Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia. After a fruitful brainstorming session, the Advisory Board supported the Phase 2b trial design, which will be initiated in 2023.

Rejuvenate Biomed started clinical trial with RJx-01 for treating sarcopenia. This trial marks Rejuvenate’s maturation from preclinical to clinical stage and is accompanied by the growth of the team and a move to the new Health Campus in Diepenbeek.

Through this investment, Rejuvenate Biomed becomes a clinical-stage company. The funding was led by Rejuveron Life Sciences and Vesalius Biocapital.

The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders.

Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections.